Skip to main content

Qiagen Clinical Insight

Qiagen has added new capabilities to the Qiagen Clinical Insight (QCI), its clinical decision support solution, which streamlines the annotation, interpretation and reporting of next-generation sequencing results for clinical laboratories.

Specifically, the company has expanded the solution to include support for leukemia and lymphoma testing as well as testing for hereditary cancers including breast and ovarian cancer, Lynch syndrome, Peutz-Jegher syndrome, ataxia telangiectasia, neurofibromatosis, hereditary diffuse gastric cancer, familial prostate cancer, polyposis, and many more. —This is in addition to existing support for analyzing somatic mutations in solid tumors. The updated software also offers new features for diagnostic testing as well as monitoring and progression, support for copy number variations and fusion genes, and additional prognostics data from the literature. It also provides comprehensive coverage of FDA- and EMA-approved drug labels, NCCN, ASCO and ESMO professional guidelines, and active genotype-related clinical trials.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.